NBIX

SEC source: 0000914475-25-000009 · wk-form4_1738195415.xml · derivative · entry 3

GORMAN KEVIN CHARLES · CIK 0001201096 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 146,105 shares

Expires 2025-02-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: The option was granted February 3, 2015 and vested in 48 equal monthly installments beginning on March 3, 2015. These options were due to expire on February 3, 2025.

SEC source: 0000914475-25-000009 · wk-form4_1738195415.xml · nonDerivative · entry 2

GORMAN KEVIN CHARLES · CIK 0001201096 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 514,596

F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2024. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $147.20 to $151.49. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F3 · balance_after: 514,596 of the outstanding shares are held by the Gorman and Blais Family Trust, of which Dr. Gorman has voting and investment power.

SEC source: 0000914475-25-000009 · wk-form4_1738195415.xml · nonDerivative · entry 1

GORMAN KEVIN CHARLES · CIK 0001201096 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 660,701

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000914475-25-000004 · wk-form4_1737149514.xml · derivative · entry 6

Gano Kyle · CIK 0001567160 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 60,188 shares

Expires 2025-02-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: The option was granted February 3, 2015 and vested in 48 equal monthly installments beginning on March 3, 2015. These options were due to expire on February 3, 2025.

SEC source: 0000914475-25-000004 · wk-form4_1737149514.xml · derivative · entry 5

Gano Kyle · CIK 0001567160 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 4,812 shares

Expires 2025-02-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: The option was granted February 3, 2015 and vested in 48 equal monthly installments beginning on March 3, 2015. These options were due to expire on February 3, 2025.

SEC source: 0000914475-25-000004 · wk-form4_1737149514.xml · nonDerivative · entry 4

Gano Kyle · CIK 0001567160 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 135,392

F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2024. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $139.53 to $142.62. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F3 · balance_after: Includes an aggregate of 226 shares purchased on February 29, 2024, from the Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan.

SEC source: 0000914475-25-000004 · wk-form4_1737149514.xml · nonDerivative · entry 3

Gano Kyle · CIK 0001567160 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 195,580

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000914475-25-000004 · wk-form4_1737149514.xml · nonDerivative · entry 2

Gano Kyle · CIK 0001567160 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 135,392

F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2024. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $139.53 to $142.62. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

SEC source: 0000914475-25-000004 · wk-form4_1737149514.xml · nonDerivative · entry 1

Gano Kyle · CIK 0001567160 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 140,204

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000914475-25-000002 · wk-form4_1735939418.xml · derivative · entry 3

Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,718

Underlying: Common Stock · 272 shares

Expires 2032-01-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The option was granted January 31, 2022 and vests in 48 equal monthly installments beginning February 28, 2022. These options will expire ten years from the date of grant on January 31, 2032.

SEC source: 0000914475-25-000002 · wk-form4_1735939418.xml · nonDerivative · entry 2

Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,507

F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on November 29, 2023.

SEC source: 0000914475-25-000002 · wk-form4_1735939418.xml · nonDerivative · entry 1

Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,779

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000914475-24-000226 · wk-form4_1734644819.xml · derivative · entry 2

ROBERTS EIRY · CIK 0001727606 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,770

Underlying: Common Stock · 27,770 shares

Expires 2034-12-17

F3 · derivative.exercise_date: Represents an option of which 1/4 of the shares underlying the option becomes vested and exercisable on February 13, 2025 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter beginning on March 13, 2025, such that the option shall fully vest on February 13, 2028.

SEC source: 0000914475-24-000226 · wk-form4_1734644819.xml · derivative · entry 1

ROBERTS EIRY · CIK 0001727606 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,487

Underlying: Common Stock · 5,487 shares

Expires not disclosed

F1 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock.

F2 · derivative.exercise_date: The Restricted Stock Units will vest 1/4 of the units on February 13, 2025, and then annually 1/4 of the shares will vest on February 13, 2026, February 13, 2027, and February 13, 2028.

F2 · derivative.expiration_date: The Restricted Stock Units will vest 1/4 of the units on February 13, 2025, and then annually 1/4 of the shares will vest on February 13, 2026, February 13, 2027, and February 13, 2028.

SEC source: 0000914475-24-000224 · wk-form4_1734644255.xml · derivative · entry 3

Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,990

Underlying: Common Stock · 1,091 shares

Expires 2032-01-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The option was granted January 31, 2022 and vests in 48 equal monthly installments beginning February 28, 2022. These options will expire ten years from the date of grant on January 31, 2032.

SEC source: 0000914475-24-000224 · wk-form4_1734644255.xml · nonDerivative · entry 2

Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,507

F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on November 29, 2023.

SEC source: 0000914475-24-000224 · wk-form4_1734644255.xml · nonDerivative · entry 1

Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 3,598

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000914475-24-000222 · wk-form4_1733269971.xml · derivative · entry 3

Onyia Jude · CIK 0001894425 · Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 4,426

Underlying: Common Stock · 4,426 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

F5 · derivative.exercise_date: This RSU was granted to the Reporting Person on November 29, 2021. In accordance with the terms of the RSU, the award vested as to 4,425 shares on November 29, 2022, vested as to 4,425 shares on November 29, 2023, vested as to 4,426 shares on November 29, 2024, and will vest as to 4,426 shares on November 29, 2025, subject to the terms and conditions of the award.

F5 · derivative.expiration_date: This RSU was granted to the Reporting Person on November 29, 2021. In accordance with the terms of the RSU, the award vested as to 4,425 shares on November 29, 2022, vested as to 4,425 shares on November 29, 2023, vested as to 4,426 shares on November 29, 2024, and will vest as to 4,426 shares on November 29, 2025, subject to the terms and conditions of the award.

SEC source: 0000914475-24-000222 · wk-form4_1733269971.xml · nonDerivative · entry 2

Onyia Jude · CIK 0001894425 · Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 15,449

F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on September 1, 2022. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $125.42 to $127.04. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F3 · balance_after: Includes an aggregate of 226 shares purchased on February 29, 2024 from the Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan.

SEC source: 0000914475-24-000222 · wk-form4_1733269971.xml · nonDerivative · entry 1

Onyia Jude · CIK 0001894425 · Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 17,780

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000914475-24-000220 · wk-form4_1731452320.xml · derivative · entry 8

ROBERTS EIRY · CIK 0001727606 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,265

Underlying: Common Stock · 1 shares

Expires 2032-01-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · derivative.exercise_date: Represents option of which 1/48th of the shares underlying the option became vested and exercisable on February 28, 2022 and an additional 1/48th of the shares underlying the option becomes vested and excercisable each month thereafter.

SEC source: 0000914475-24-000220 · wk-form4_1731452320.xml · derivative · entry 7

ROBERTS EIRY · CIK 0001727606 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 971 shares

Expires 2030-02-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: Represents option of which 1/48th of the shares underlying the option became vested and exercisable on March 6, 2020 and an additional 1/48th of the shares underlying the option became vested and excercisable each month thereafter.

SEC source: 0000914475-24-000220 · wk-form4_1731452320.xml · derivative · entry 6

ROBERTS EIRY · CIK 0001727606 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,233 shares

Expires 2029-02-07

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: Represents option of which 1/48th of the shares underlying the option became vested and exercisable on March 7, 2019 and an additional 1/48th of the shares underlying the option became vested and excercisable each month thereafter.

SEC source: 0000914475-24-000220 · wk-form4_1731452320.xml · derivative · entry 5

ROBERTS EIRY · CIK 0001727606 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 5,140 shares

Expires 2028-01-08

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: Represents option of which 1/4th of the shares underlying the option became vested and exercisable on January 8, 2019 and an additional 1/48th of the shares underlying the option became vested and excercisable each month thereafter.

SEC source: 0000914475-24-000220 · wk-form4_1731452320.xml · nonDerivative · entry 4

ROBERTS EIRY · CIK 0001727606 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 31,061

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction involved a cash exercise of a stock option without a subsequent sale of the underlying shares of common stock.

F2 · balance_after: 29,876 of the outstanding shares are held by The Stephen Tayor and Eiry W. Roberts Joint Trust Agreement, of which Dr. Roberts has voting and investment power.

SEC source: 0000914475-24-000220 · wk-form4_1731452320.xml · nonDerivative · entry 3

ROBERTS EIRY · CIK 0001727606 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 31,060

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction involved a cash exercise of a stock option without a subsequent sale of the underlying shares of common stock.

SEC source: 0000914475-24-000220 · wk-form4_1731452320.xml · nonDerivative · entry 2

ROBERTS EIRY · CIK 0001727606 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,089

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction involved a cash exercise of a stock option without a subsequent sale of the underlying shares of common stock.

SEC source: 0000914475-24-000220 · wk-form4_1731452320.xml · nonDerivative · entry 1

ROBERTS EIRY · CIK 0001727606 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,856

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction involved a cash exercise of a stock option without a subsequent sale of the underlying shares of common stock.

SEC source: 0000914475-24-000218 · wk-form4_1731026551.xml · nonDerivative · entry 1

SHERWIN STEPHEN A · CIK 0001079462 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 24,504

F1 · kind: This transaction represents a gift/charitable contribution effective November 4, 2024. This is not a market transaction, thus no price has been reported. No value was received for the gifted shares.

SEC source: 0000914475-24-000216 · wk-form4_1730505118.xml · derivative · entry 2

Gano Kyle · CIK 0001567160 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,344

Underlying: Common Stock · 13,344 shares

Expires 2034-11-01

F3 · derivative.exercise_date: Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on December 1, 2024 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter.

SEC source: 0000914475-24-000216 · wk-form4_1730505118.xml · derivative · entry 1

Gano Kyle · CIK 0001567160 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,455

Underlying: Common Stock · 2,455 shares

Expires not disclosed

F1 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock.

F2 · derivative.exercise_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of November 1, 2025, November 1, 2026, November 1, 2027, and November 1, 2028.

F2 · derivative.expiration_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of November 1, 2025, November 1, 2026, November 1, 2027, and November 1, 2028.

SEC source: 0000914475-24-000203 · wk-form4_1728333186.xml · nonDerivative · entry 1

Boyer David W. · CIK 0001909817 · Chief Corp. Affairs Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 377

F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2024. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

SEC source: 0000914475-24-000201 · wk-form4_1726604500.xml · nonDerivative · entry 1

Boyer David W. · CIK 0001909817 · Chief Corp. Affairs Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,672

F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2024. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $120.31 to $122.48. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F3 · balance_after: Includes an aggregate of 238 shares purchased on February 29, 2024 and August 30, 2024 from the Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan.

SEC source: 0000914475-24-000197 · wk-form4_1723842044.xml · nonDerivative · entry 1

RASTETTER WILLIAM H · CIK 0001205903 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 37,491

F1 · price: The Reporting Person contributed Issuer common stock to an exchange fund for shares of the exchange fund. The Issuer common stock was valued at $146.69 per share for the purpose of determining the number of shares of the exchange fund issuable to the Reporting Person.

F2 · balance_after: All of the reported shares are held by the Rastetter Family Trust established September 2, 2010, of which the Reporting Person has voting and investment power.

SEC source: 0000914475-24-000195 · wk-form4_1723756911.xml · derivative · entry 3

LYONS GARY A · CIK 0001123343 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 11,570 shares

Expires 2025-05-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: The option was granted May 28, 2015 and vested in 12 equal monthly installments beginning June 28, 2015. These options will expire ten years from the date of grant on May 28, 2025.

SEC source: 0000914475-24-000195 · wk-form4_1723756911.xml · nonDerivative · entry 2

LYONS GARY A · CIK 0001123343 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 119,047

F2 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on February 13, 2024

F3 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $150.00 to $151.30. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range

F1 · ownership.direct: 113,064 of the reported shares are held by the Gary A. Lyons Revocable Living Trust U/A 6/8/12, of which the Reporting Person has voting and investment power.

SEC source: 0000914475-24-000195 · wk-form4_1723756911.xml · nonDerivative · entry 1

LYONS GARY A · CIK 0001123343 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 130,617

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · ownership.direct: 113,064 of the reported shares are held by the Gary A. Lyons Revocable Living Trust U/A 6/8/12, of which the Reporting Person has voting and investment power.

SEC source: 0000914475-24-000193 · wk-form4_1723756315.xml · derivative · entry 3

ABERNETHY MATT · CIK 0001724097 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 14,100 shares

Expires 2027-12-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: Option granted December 1, 2017 and vested at 25% upon the first anniversary (December 1, 2018) and the remaining 75% vested in 36 equal monthly installments beginning January 1, 2019.

SEC source: 0000914475-24-000193 · wk-form4_1723756315.xml · nonDerivative · entry 2

ABERNETHY MATT · CIK 0001724097 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 31,528

F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on February 13, 2024. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan

F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $150.00 to $151.35. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

SEC source: 0000914475-24-000193 · wk-form4_1723756315.xml · nonDerivative · entry 1

ABERNETHY MATT · CIK 0001724097 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 45,628

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000914475-24-000191 · wk-form4_1723755955.xml · derivative · entry 4

Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 22,049

Underlying: Common Stock · 3,043 shares

Expires 2033-02-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 13, 2023 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter.

SEC source: 0000914475-24-000191 · wk-form4_1723755955.xml · nonDerivative · entry 3

Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,507

F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on November 29, 2023.

F3 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $150.00 to $150.28. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

SEC source: 0000914475-24-000191 · wk-form4_1723755955.xml · nonDerivative · entry 2

Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 6,607

F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on November 29, 2023.

F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $150.00 to $150.44. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

SEC source: 0000914475-24-000191 · wk-form4_1723755955.xml · nonDerivative · entry 1

Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 9,650

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000914475-24-000189 · wk-form4_1723151810.xml · derivative · entry 3

Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 4,081

Underlying: Common Stock · 273 shares

Expires 2032-01-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The option was granted January 31, 2022 and vests in 48 equal monthly installments beginning February 28, 2022. These options will expire ten years from the date of grant on January 31, 2032.

SEC source: 0000914475-24-000189 · wk-form4_1723151810.xml · nonDerivative · entry 2

Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 6,607

F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on November 29, 2023.

SEC source: 0000914475-24-000189 · wk-form4_1723151810.xml · nonDerivative · entry 1

Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 6,880

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000914475-24-000187 · wk-form4_1722894030.xml · derivative · entry 3

Cooke Julie · CIK 0001776977 · Chief Human Resources Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 12,632 shares

Expires 2027-10-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: Represents option of which 1/4th of the shares underlying the option becomes vested and exercisable on October 2, 2018 and an additional 1/48th of the shares underlying the option becomes vested and excercisable each month thereafter.

SEC source: 0000914475-24-000187 · wk-form4_1722894030.xml · nonDerivative · entry 2

Cooke Julie · CIK 0001776977 · Chief Human Resources Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 18,202

F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 14, 2024.

F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $150.53 to $156.51. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F3 · balance_after: 16,538 of the reported shares are held by the Cooke Family Trust of 2004 U/A 12/28/2004, of which the Reporting Person has voting and investment power.

SEC source: 0000914475-24-000187 · wk-form4_1722894030.xml · nonDerivative · entry 1

Cooke Julie · CIK 0001776977 · Chief Human Resources Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 30,834

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.